Cellceutix Pharmaceuticals, Inc. (OTCBB: CTIX), located outside of Boston in Beverly, MA, is an emerging bio-pharmaceutical company in the business of developing small molecule therapies in areas of unmet medical need. Their primary efforts are in cancer and inflammatory disease, but also have another product in the pipeline that is being formulated to treat autism. Cellceutix flagship product, Kevetrin, is being developed to treat cancers that are resistant to standard treatments. Recently, Cellceutix has announced some exciting results in animal models of multi-drug resistant lung cancer.
Their business strategy is well-described by their company slogan “Compounds for Cures.” Cellceutix has kept a “low profile” as they have been developing their products with the ethical philosophy of their products alone will help patients and this will translate into rewards for shareholders. By biotechnology standards, their pipeline of products is moving forward rapidly through an experienced management and development team with years of experience in researching, developing and marketing pharmaceuticals. By “Over The Counter Bulletin Board” standards, their ethics are virtually unparalleled.
To quote the Cellceutix CEO, George Evans:
Biotech companies have a tendency to talk excitedly about a lot of very complicated science. The excitement is, of course, genuine as the companies see great promise in what they are doing. But how do we understand what it all means? Just like a lot of other companies, we are doing a lot of very complicated experiments and coming up with a lot of dense data and great graphs. And we really like what we see. I think in our case, however, it is easy to explain what it all means. First, it means that we’ve accomplished a lot in a short time. And second it means that our lead compound, Kevetrin, is showing great promise in treating tumors that are otherwise very difficult to treat. This means hope for patients and value for shareholders.
HISTORY OF CELLCEUTIX CORPORATION
Cellceutix was established in May of 2007 by Chief Executive Officer, George W. Evans and Chief Scientific Officer, Dr. Krishna Menon. Both have extensive backgrounds and years of experience in all aspects of biopharmaceuticals.
Mr. Evans has more than 25 years of experience in the industry with a great portion of that time spent with Pfizer, Inc. where he was in high-level management. He ending his career there as General Counsel for Pfizer’s worldwide prescription drug unit, and a member of the unit’s leadership team. Mr. Evan’s background also includes being a member of the Editorial Advisory Board and the Finance Committee of the Food and Drug Law Institute and a member of the Board of the City Bar Fund. He is a graduate of Williams College and Columbia University’s Law and Business schools.
Dr. Krishna Menon’s experience and accolades are impressive to say the least. Dr. Menon has nearly 40 years experience in drug development for academia and industry. Some of the highlights of Dr. Menon’s career include:
- Chief Government Veterinarian for a major Parish in Jamaica
- Director of Agriculture for the Cayman Islands in the British Caribbean
- Research Scientist under the acclaimed oncologist, Dr. Emil Frei, at the Dana Farber Cancer Research Institute
- Senior Research Scientist, In Vivo Research (Cancer), at Bayer Pharmaceuticals (Miles Laboratories)
- Operating his own veterinary oncology and drug development consultancy practice
- Group Leader, Cancer In Vivo Research and Clinical Development, for Eli Lilly
- Recipient of the President’s Recognition Award by Lily (This is an award not bestowed annually but rather on only special occasions)
The final component of Cellceutix solid corporate structure is their Chief Financial Officer, Leo Ehrlich. Mr. Ehrlich has been with Cellceutix since June of 2007. A Certified Public Accountant, Mr. Ehrlich also his his BBA from Bernard Baruch College of the City University of New York and sits on the board at StatSure Diagnostic Systems, Inc. as their Chief Financial Officer. Before coming to Cellceutix, Mr. Ehrlich Mr. Ehrlich was the CFO and a director of Nanoviricides, Inc. from June 1, 2005. until May 2007.
SHARE STRUCTURE (approximate as of March 25, 2010)
Authorized Shares: 300,000,000
Outstanding Shares: 98,000,000
Float: 40,000,000
TRANSFER AGENT
Pacific Stock Transfer Co.
4045 South Spencer Street
Suite 403
Las Vegas, NV 89119
Tel: (702) 361-3033
Fax: (702) 433-1979
E-mail: info@pacificstocktransfer.com
CONTACT INFORMATION
Cellceutix Corporation
100 Cumming Center
Suite 151-B
Beverly, MA 01915
Phone: 978-633-3623
Fax: 978-921-6564
Email: info@cellceutix.com
Website: http://www.cellceutix.com
